论文部分内容阅读
肿瘤转移是造成乳腺癌患者死亡的主要原因,为提高生存期,有大约80%的患者选择了辅助治疗,然而只有其中一部分患者最后真正发生了转移。那些实际转移风险很低,却仍然选择了进一步放疗、化疗、内分泌或免疫治疗的患者,不仅受到了治疗副作用的伤害、也造成了医疗资源的浪费。因此,准确评价患者的转移风险对指导临床工作格外重要。以肿瘤的基因改变和转移过程为切入点,利用先进的分子技术,已有数项指标通过严谨的实验论证,认为可以评估乳腺癌的转移风险,本文将对其进行简要的介绍和分析。
Tumor metastasis is the leading cause of death in breast cancer patients. About 80% of patients chose adjuvant therapy to improve their survival. However, only a few of them eventually actually metastasized. Patients who have a very low risk of actual metastases but who still opt for further radiotherapy, chemotherapy, endocrine or immunotherapy are not only harmed by the side effects of treatment but also a waste of medical resources. Therefore, accurate assessment of the risk of metastasis in patients with clinical guidance is particularly important. Taking the process of tumor gene mutation and metastasis as the starting point, using advanced molecular techniques, several indicators have passed the rigorous experimental demonstration, that can assess the risk of breast cancer metastasis, this article will be briefly introduced and analyzed.